How should capital allocate across U.S. life sciences real estate in 2026 given the post-2022 vacancy reset, the shift from lab-office to cGMP manufacturing, and the widening gap between established clusters and emerging Texas nodes?

Life sciences is no longer a generic growth story. In 2026 it is a basis-and-cluster story. The best capital should separate three buckets: established Tier 1 clusters that remain strategically dominant but are still digesting oversupply, Tier 2 clusters where the pipeline has shut off and basis may now be more attractive than the headline vacancy implies, and emerging Texas nodes that are strategically important but not yet broad institutional deployment markets.

• The 2021-2022 lab boom is over. Vacancy is now high enough in Boston, San Diego, and Raleigh-Durham that no market should be underwritten as if lab demand is still supply-constrained across the board.
• Cluster strength still matters more than cheapness. Boston and San Diego remain the two strongest deployable clusters in this source set because tenant density, research anchors, and regulatory stickiness are real even while the market is resetting.
• Pipeline shutoff matters. Raleigh-Durham's most important number is not just 32.3% vacancy; it is 0 SF under construction. That is what makes the market interesting for capital willing to buy through the reset.
• Texas is a strategic option on future depth, not yet a proven broad allocation market. The source trail is strong on campus formation and institutional anchors, but weak on rents, vacancy, and transaction evidence compared with Boston, San Diego, and RTP.
• South San Francisco is intentionally not given its own bucket here because the current repo source layer is still thinner than Boston, San Diego, and RTP and does not yet support a comparably defensible allocation call.

• Boston is best for capital that wants the deepest global biotech cluster and can be patient on lease-up. It is weakest for investors who need near-term mark-to-market rent momentum.
• San Diego is best for capital that can distinguish Torrey Pines and UTC from Sorrento Mesa's larger spec overhang. It is weaker for buyers treating the whole market as one uniform lab corridor.
• Raleigh-Durham is best for opportunistic investors who want a real life sciences ecosystem without paying Boston or San Diego basis. It is weaker for investors who require a currently tight market rather than a reset market.
• Houston works for strategic capital that believes institutional healthcare and research anchors can compound into a real life sciences district around TMC. It is weaker for anyone pretending Houston already has the same depth as the coastal clusters.
• Dallas works for early thematic capital that values Pegasus Park's incubator-to-graduation pathway. It is weakest for large capital that needs immediate market depth and a fully formed tenant base.

The most important underwriting shift is that demand is moving away from speculative lab-office as a generic venture-growth trade and toward cGMP manufacturing and validated production environments. That changes the allocation map:

• Boston and San Diego remain the primary R&D cluster markets, but broad office-like lab supply is still working through excess inventory.
• Raleigh-Durham looks more interesting today as a value and conversion market because its construction pipeline has already shut down.
• Houston and Dallas are more attractive as future manufacturing and institutional-anchor stories than as current pure-play lab-office markets.

• Do not treat high vacancy in Boston or San Diego as proof that the cluster thesis broke. The source trail points to a supply-cycle reset, not a collapse in scientific relevance.
• Do not treat Texas campus formation as proof that Houston or Dallas are already scaled life sciences markets. The repo's Texas source note is explicit that the boom is "not quite there yet."
• Do not underwrite generic flex or office product as interchangeable with real life sciences space. Regulatory stickiness, MEP intensity, and TI reload risk still define the asset class.

This is the first national allocation note in the graph for a specialized asset class that already has both an underwriting page and a geography page. It turns Life Sciences and Lab Underwriting and Life Sciences Cluster Geography into a capital-deployment decision rather than leaving them as parallel reference pages.

• Analyses Hub
• Life Sciences Cluster Geography
• Life Sciences and Lab Underwriting
• Boston
• San Diego
• Charlotte and Raleigh-Durham
• Texas Medical Center District
• Dallas-Fort Worth

All figures sourced from data/properties.db market_observations. Geography filter: property_type = 'Life Sciences' or name LIKE '%Life%'. Sources: Hunneman / C&W / Colliers / Lincoln LPC (Boston); C&W / Savills / Newmark / CBRE (San Diego); C&W (Raleigh-Durham).

Submarket vacancy (Q3 2025, C&W): Torrey Pines 10.2% on 6.2M SF (tightest), UTC/Campus Point 16.6% on 3.6M SF, Sorrento Mesa 39.7% on 7.6M SF (highest), Sorrento Valley 38.0% on 1.6M SF.

Note: Savills flagged ~5 former Pfizer buildings expected to hit the market, potentially pushing wet lab availability to ~45%.

The pipeline-shutoff metric is Raleigh-Durham's most important structural signal: 0 SF under construction as of Q2 2025 means no new dilutive supply is coming even as vacancy resets toward a trough.

No structured market observations (vacancy, rent, absorption) for Houston or Dallas life sciences are in the DB. The Texas source note covers cluster formation and institutional anchors only. The allocation call for Houston (TMC/Helix Park) and Dallas (Pegasus Park) is derived from qualitative source note analysis, not from market-rate comparables.

• Houston and Dallas life sciences market data: No vacancy, rent, or absorption observations exist in the DB for Houston or Dallas life sciences geographies. Allocation calls for Texas nodes rely entirely on qualitative source notes.
• South San Francisco: No South San Francisco / Bay Area life sciences observations are in the DB. This cluster is intentionally excluded from the allocation frame given the thin source layer, but no data is available to reconsider that decision.
• Boston submarket breakdown: Cambridge is tracked separately in the DB, but other Boston-area submarkets (Route 128 corridor, Seaport, Waltham) have no individual geography entries. The metro vacancy divergence between Cambridge (12.7%) and the broader metro (28.8%) is notable but incompletely characterized.
• Capital markets / transaction data: No investment sales volume, cap rate, or price-per-SF observations exist in the DB for any life sciences market. The basis-reset thesis for Boston and San Diego cannot be quantified from current structured data.
• cGMP and manufacturing space: The DB does not distinguish lab-office from cGMP/manufacturing space in any of the tracked markets. The allocation note's most important structural argument (the shift toward cGMP) has no supporting quantitative layer in the DB.
• Raleigh-Durham — Q3/Q4 2025 update: The most recent RTP observations are as of Q2 2025. No Q3 or Q4 2025 C&W or CBRE report has been imported yet.

• Boston Market Intelligence 2025
• San Diego Market Intelligence 2025-2026
• Raleigh-Durham Market Intelligence 2025
• Source: Life Sciences: The Next Frontier for Commercial Real Estate in Texas?